Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
20166.0k citationsDaniel A. Arber, Attilio Orazi et al.Bloodprofile →
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
20093.0k citationsJames W. Vardiman, Jüergen Thiele et al.Bloodprofile →
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
19992.5k citationsJames W. Vardiman, Clara D. Bloomfield et al.profile →
The World Health Organization (WHO) classification of the myeloid neoplasms
20021.5k citationsJames W. Vardiman et al.Bloodprofile →
Diagnostic criteria and classification of mastocytosis: a consensus proposal
2001738 citationsJames W. Vardiman, John M. Bennett et al.profile →
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
2007604 citationsAyalew Tefferi, Jüergen Thiele et al.Bloodprofile →
Association of an Inversion of Chromosome 16 with Abnormal Marrow Eosinophils in Acute Myelomonocytic Leukemia
1983394 citationsMichelle M. Le Beau, Richard A. Larson et al.New England Journal of Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by James W. Vardiman
Since
Specialization
Citations
This map shows the geographic impact of James W. Vardiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Vardiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Vardiman more than expected).
Fields of papers citing papers by James W. Vardiman
This network shows the impact of papers produced by James W. Vardiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Vardiman. The network helps show where James W. Vardiman may publish in the future.
Co-authorship network of co-authors of James W. Vardiman
This figure shows the co-authorship network connecting the top 25 collaborators of James W. Vardiman.
A scholar is included among the top collaborators of James W. Vardiman based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with James W. Vardiman. James W. Vardiman is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Arber, Daniel A., Attilio Orazi, Robert P. Hasserjian, et al.. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127(20). 2391–2405.6033 indexed citations breakdown →
Tefferi, Ayalew, Jüergen Thiele, Attilio Orazi, et al.. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 110(4). 1092–1097.604 indexed citations breakdown →
Golomb, Harvey M. & James W. Vardiman. (2003). Diagnosis of hairy cell leukemia. The Journal of Physical Chemistry B. 112(23). 7132–9.1 indexed citations
13.
Larson, Richard A., Michelle M. LeBeau, James W. Vardiman, & Janet D. Rowley. (1996). Myeloid Leukemia after Hematotoxins. Environmental Health Perspectives. 104. 1303–1303.10 indexed citations
Ratain, Mark J., James W. Vardiman, & Harvey M. Golomb. (1986). The role of interferon in the treatment of hairy cell leukemia.. PubMed. 13(3 Suppl 2). 21–8.11 indexed citations
Beau, Michelle M. Le, Richard A. Larson, Mitchell A. Bitter, et al.. (1983). Association of an Inversion of Chromosome 16 with Abnormal Marrow Eosinophils in Acute Myelomonocytic Leukemia. New England Journal of Medicine. 309(11). 630–636.394 indexed citations breakdown →
20.
Rowley, Janet D., Harvey M. Golomb, & James W. Vardiman. (1977). Nonrandom Chromosomal Abnormalities in Acute Nonlymphocytic Leukemia in Patients Treated for Hodgkin Disease and Non-Hodgkin Lymphomas. 50(5). 759–770.195 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.